Executive Summary
Multiple myeloma has become the most iteratively developed hematologic malignancy of the past two decades, with the FDA issuing 54 approval decisions spanning 22 distinct INNs across 2003–2026 in the Nexus dataset Nexus FDA Dataset. The EMA has issued 53 matched approval decisions across 20 INNs over the same period Nexus EMA Dataset. The regulatory trajectory shows three distinct eras: proteasome inhibitor / IMiD foundational approvals (2003–2015), CD38 monoclonal antibody and triplet/quadruplet standardisation (2015–2022), and BCMA/GPRC5D T-cell redirection with MRD-endpoint acceptance (2022–2026). As of 2022, median OS for newly diagnosed MM is 7–10 years, reflecting the cumulative impact of these approvals (Rajkumar, 2022; Miller & Usmani, 2026[1]) FDA Guidance: Minimal Residual Disease and CR in Multiple Myeloma_Supporting Accelerated Approval_Draft.
The most consequential recent regulatory event is FDA's endorsement — following unanimous ODAC vote on 12-Apr-24 — of MRD-negative CR as a primary endpoint supporting Accelerated Approval in MM ODAC Apr 2024: MRD in Multiple Myeloma. This shift is already visible in the dataset: iberdomide (Zenbexus, IberDd) received AA on 13-Aug-26 with MRD-negative CR as the primary endpoint (41% vs 21%, p<0.0001) Nexus FDA Dataset, and daratumumab-VRd (CEPHEUS) converted to traditional approval on 27-Jan-26 on MRD negativity co-primary (52.3% vs 34.8%, p=0.0005) Nexus FDA Dataset. On the EMA side, isatuximab-VRd (GMMG-HD7) received standard MA on 18-Jul-25 on MRD negativity as primary endpoint Nexus EMA Dataset, and daratumumab-VRd (PERSEUS/MMY3014) received orphan/standard MA on 21-Oct-24 with MRD-guided treatment discontinuation embedded in the SmPC Nexus EMA Dataset.
The BCMA and GPRC5D T-cell redirector wave — Abecma (ide-cel), Carvykti (cilta-cel), Tecvayli (teclistamab), Talvey (talquetamab), Elrexfio (elranatamab), Lynozyfic (linvoseltamab) — has moved from 5L+ AA labels (2021–2023) to 2L traditional approval, exemplified by Carvykti CARTITUDE-4 (HR 0.41 for PFS) and Tecvayli-Dara MajesTEC-3 approval on 05-Mar-26 (HR 0.17 for PFS, HR 0.46 for OS) Nexus FDA Dataset. This is a textbook "AA-to-traditional" line-expansion arc (Costa et al., 2026[2]; Rodriguez-Otero et al., 2024[12]).
The remaining strategic white space is well-defined: post-BCMA/GPRC5D resistance biology, extramedullary disease (EMD), high-risk cytogenetics (t(4;14), del(17p), 1q21+), and MRD-guided treatment de-escalation with regulatory-grade evidence. With 921 active/recruiting interventional trials globally, competitive intensity in relapsed/refractory settings is at an all-time high — differentiation will come from novel MOAs (trispecifics, CELMoDs, novel targets) or from MRD-anchored fixed-duration paradigms.
54FDA Multiple Myeloma Approvals
53EMA Multiple Myeloma Approvals
921Active Clinical Trials
Disease Landscape & Unmet Need
Multiple myeloma is a clonal plasma cell malignancy accounting for approximately 18% of all hematologic malignancies in the United States FDA Guidance: Minimal Residual Disease and CR in Multiple Myeloma_Supporting Accelerated Approval_Draft. Since 2003, more than 20 new drugs or biologics have been approved for MM, transforming what was a median 3-year survival disease into one where median OS in newly diagnosed patients now reaches 7–10 years (Rajkumar, 2022; Miller & Usmani, 2026[1]). Despite this progress, MM remains incurable, and virtually all patients cycle through remission and relapse, with each successive line of therapy delivering diminishing PFS (Mushtaq et al., 2025[3]).
Disease heterogeneity is the central clinical and regulatory challenge. The 2025 IMS/IMWG consensus on high-risk MM explicitly rejected legacy prognostic staging and reframed high-risk MM around cumulative cytogenetic burden — del(17p), t(4;14), t(14;16), 1q21+ gains — and functional markers such as extramedullary disease (Avet-Loiseau et al., 2025[7]). EMD in particular remains a poorly served subset: spatial transcriptomics shows profound subclonal heterogeneity and T-cell dysfunction that likely explains resistance to bispecifics and CAR-T (John et al., 2024[11]; Bladé et al., 2022[20]; Bansal et al., 2021[21]). Notably, high-risk cytogenetics were present in 22–35% of pivotal trial populations across the recent BCMA CAR-T and bispecific studies, but subgroup benefit magnitudes have been inconsistent.
The current standard-of-care frame differs by transplant eligibility. For transplant-eligible NDMM, quadruplet induction with anti-CD38 mAb + PI + IMiD + dexamethasone (DVTd, D-VRd) has become the reference regimen following CASSIOPEIA and PERSEUS long-term data (Moreau et al., 2019[24]; Moreau et al., 2024[19]; Ebraheem et al., 2024[16]). For transplant-ineligible NDMM, D-Rd (MAIA) delivers median PFS >60 months and OS benefit in mature follow-up (Facon et al., 2025[9]), with Isa-VRd (IMROZ, BENEFIT) now offering a proteasome-inhibitor-anchored quadruplet alternative (Leleu et al., 2024[18]). For relapsed disease, sequential exposure to daratumumab, then a bispecific or CAR-T, has become the modal patient journey (Dimopoulos et al., 2021[22]; van de Donk et al., 2025[8]).
The residual unmet need concentrates in four clinically distinct populations: (1) triple-class-refractory patients who have progressed on both a BCMA-directed therapy and daratumumab; (2) extramedullary disease with poor T-cell fitness; (3) high-risk cytogenetic subsets who under-benefit from every regimen tested to date; and (4) high-risk smouldering MM, where the AQUILA trial has now established daratumumab monotherapy as a disease-modifying intervention (Dimopoulos et al., 2025[4]) but where the regulatory frame remains restricted to the high-risk subset.
FDA Regulatory Precedents — 54 matched records (2000–2025)
| Drug (Brand) | Sponsor | Approval | Pathway | Primary Endpoint | Line | Type |
|---|
| Iberdomide (Zenbexus) | BMS | 13-Aug-26 | AA + BTD + PR + Orbis | MRD-neg CR | 2L | New INN |
| Isatuximab SC (Sarclisa Escena) | Sanofi | 10-Jul-26 | Traditional | ORR (SC bridge) | 1L/2L | Formulation |
| Teclistamab + Dara SC (Tecvayli) | Janssen | 05-Mar-26 | Trad + BTD + PR + RTOR + Orbis | PFS | 2L | Line expansion |
| Daratumumab-VRd (Darzalex Faspro CEPHEUS) | Janssen | 27-Jan-26 | Traditional | MRD-neg % | 1L | Line expansion |
| Daratumumab (Darzalex Faspro AQUILA) | Janssen | 06-Nov-25 | Traditional | ORR (PFS-to-MM) | 1L SMM | New indication |
| Belantamab mafodotin (Blenrep) | GSK | 23-Oct-25 | Traditional | PFS | 3L | Re-launch |
| Linvoseltamab (Lynozyfic) | Regeneron | 02-Jul-25 | AA + PR + FT | ORR | 5L | New INN |
| Isatuximab (Sarclisa IMROZ) | Sanofi | 20-Sep-24 | Trad + PR | PFS | 1L | Line expansion |
| Daratumumab-VRd (Darzalex Faspro PERSEUS) | Janssen | 30-Jul-24 | Trad + PR | PFS | 1L TE | Line expansion |
| Ciltacabtagene autoleucel (Carvykti) | Janssen/Legend | 05-Apr-24 | Traditional | PFS | 2L | Line expansion |
Showing 10 of 54 matched precedents — prioritising recent and Breakthrough-designated approvals. ✦ Go Deeper below expands the analysis. Visit the Analytics dashboards under the Analytics tab to explore all 54 precedents with interactive filters and visualisations. Nexus FDA Dataset
Landmark Approval Profiles
Iberdomide (Zenbexus) — 13-Aug-26, Accelerated Approval + Breakthrough + Priority Review + Project Orbis
Indication: IberDd combination for adult patients with relapsed or refractory multiple myeloma who have received one or two prior lines of therapy (EXCALIBER-RRMM)
Endpoint: MRD-negative CR at any time · Line: 2L · Class: Cereblon-modulating protein degrader
The first MM approval anchored on MRD-negative CR as the primary endpoint following the April 2024 ODAC endorsement. In the EXCALIBER-RRMM primary efficacy population (N=420), IberDd achieved 41% MRD-neg CR versus 21% for DVd (p<0.0001). The boxed warning covers embryo-fetal toxicity and thromboembolism, with REMS restriction. High-risk cytogenetics were present in 22%; extramedullary disease in 11%. Nexus FDA Dataset
Teclistamab + Daratumumab SC (Tecvayli MajesTEC-3) — 05-Mar-26, Traditional + Breakthrough + Priority Review + RTOR + Project Orbis
Indication: Combination with subcutaneous daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy including a proteasome inhibitor and lenalidomide
Endpoint: PFS · Line: 2L · Class: BCMA×CD3 bispecific
MajesTEC-3 (N=587) delivered median PFS not reached in the tec-dara arm versus 18.1 months in DPd/DVd control, HR 0.17 (95% CI 0.12–0.23; p<0.0001). Median OS also favoured the combination arm (HR 0.46, 95% CI 0.32–0.65; p<0.0001). The label carries a boxed warning for CRS and ICANS with mandatory REMS enrolment. This is the earliest-line BCMA bispecific approval to date and effectively repositions teclistamab from 5L monotherapy (Oct-22 AA) to a 2L combination anchor. Nexus FDA Dataset
Daratumumab-VRd (Darzalex Faspro CEPHEUS) — 27-Jan-26, Traditional
Indication: Combination with bortezomib, lenalidomide and dexamethasone for adult patients with newly diagnosed multiple myeloma who are ineligible for ASCT or refuse ASCT as initial therapy
Endpoint: Overall MRD-negativity rate · Line: 1L · Class: CD38 mAb
CEPHEUS (N=395) demonstrated MRD-negativity of 52.3% in D-VRd versus 34.8% in VRd (p=0.0005), with PFS HR 0.60 (95% CI 0.41–0.88; p=0.0078). High-risk cytogenetics present in 13% of patients. This approval is a landmark for MRD as a co-registrational endpoint in the 1L transplant-ineligible setting and cements the quadruplet regimen as SoC. Nexus FDA Dataset
Ciltacabtagene autoleucel (Carvykti CARTITUDE-4) — 05-Apr-24, Traditional
Indication: Adult patients with relapsed and lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent
Endpoint: PFS · Line: 2L · Class: BCMA CAR-T
CARTITUDE-4 (N=419) delivered median PFS not estimable versus 12 months for DPd/PVd standard therapy, HR 0.41 (95% CI 0.30–0.56); 12-month PFS rate 75.9% vs 49.5%. The label carries boxed warnings for CRS, ICANS, Parkinsonism, and Guillain-Barré. This is the definitive "AA-to-traditional" line-expansion arc in the BCMA class — cilta-cel originally received traditional approval at 5L (Feb-22) on CARTITUDE-1 ORR of 97.9%, and now anchors 2L relapsed lenalidomide-refractory disease. Nexus FDA Dataset
Daratumumab SC (Darzalex Faspro AQUILA) — 06-Nov-25, Traditional
Indication: Monotherapy for adult patients with high-risk smouldering multiple myeloma
Endpoint: PFS (progression to MM) · Line: 1L SMM · Class: CD38 mAb
AQUILA (N=390) established the first pre-symptomatic MM intervention: median PFS not evaluable in dara arm versus 41.5 months in active monitoring, HR 0.49 (95% CI 0.36–0.67; p<0.0001). May 2025 ODAC voted 6–2 in favour of the benefit-risk profile. The label is strictly restricted to high-risk SMM meeting ≥2 of three defined criteria — a rare instance of a regulatory-mandated biomarker-selected precursor disease indication. Nexus FDA Dataset
The 54 FDA records reveal three distinct regulatory eras. The foundational era (2003–2013) established the PI + IMiD scaffold through Velcade (bortezomib, first AA on ORR May-03, converted to traditional on TTP Mar-05, then advanced to 1L on TTP Jun-08), Thalomid (May-06 AA), Revlimid (Jun-06 traditional on TTP), Pomalyst (Feb-13 AA on ORR), and Kyprolis (Jul-12 AA on ORR, converted to traditional Jan-16 on ENDEAVOR PFS). Every drug in this era followed the AA-then-convert pathway. The CD38 era (2015–2021) was defined by daratumumab's Nov-15 AA on ORR (DREAMM-2 pattern), followed by rapid line expansion — MAIA (Jun-19), MMY3007/ALCYONE (May-18), CASTOR, POLLUX, CASSIOPEIA — nearly all directly on traditional approval with PFS. Isatuximab (Mar-20, IKEMA 2021, IMROZ 2024) followed the same trajectory. The immunotherapy era (2021–2026) repeated the AA-then-traditional arc for BCMA CAR-Ts (Abecma AA Mar-21 → traditional KarMMa-3 Apr-24; Carvykti traditional CARTITUDE-1 Feb-22 on 97.9% ORR → CARTITUDE-4 Apr-24) and bispecifics (Tecvayli AA Oct-22 → MajesTEC-3 Mar-26; Talvey AA Aug-23; Elrexfio AA Aug-23; Lynozyfic AA Jul-25).
Endpoint evolution is the single most important regulatory pattern. Of 54 FDA records, 26 used PFS and 18 used ORR as primary — but the temporal composition matters more than the aggregate. Every 5L+ single-arm AA approval used ORR (with DoR). Every randomised 2L+ approval since 2015 used PFS. Only two records used MRD-negative response (iberdomide 2026 AA; daratumumab-VRd CEPHEUS 2026 traditional), but both are within the last twelve months — consistent with the April 2024 ODAC vote unanimously endorsing MRD for AA (Chandhok & Sekeres, 2025[27]). Twelve records carried Breakthrough Therapy designation, disproportionately concentrated in BCMA/GPRC5D therapies (Blenrep, Carvykti, Abecma, Tecvayli, Talvey, Elrexfio, Zenbexus).
Notable AdCom activity: the Feb-19 ODAC on selinexor voted 8–5 to delay approval pending BOSTON results — FDA nonetheless granted AA — establishing a precedent that FDA will overrule adverse ODAC votes when unmet need is severe. The Jul-20 ODAC on Blenrep voted 12–0 in favour, but the drug was later voluntarily withdrawn (Nov-22) after DREAMM-3 failed, then re-approved Oct-25 on DREAMM-7 as an ADC "come-back". The May-25 ODAC on daratumumab in HR-SMM voted 6–2 in favour, with dissenting concern about over-treating a precursor disease.
Pathway acceleration is now the norm rather than the exception in this indication. Of the 6 most recent BLA/NDA approvals in the dataset (2025–2026), all six carried Priority Review; four carried Breakthrough; three used Project Orbis; two used RTOR. Time-to-approval for the recent MajesTEC-3, CEPHEUS, and IberDd submissions was compressed by 2–4 months versus PDUFA goal dates, reflecting the maturity of the FDA-OCE reviewer familiarity with the MM datasets and endpoints.
Key Regulatory Pattern: Multiple myeloma is the archetypal "surrogate endpoint maturation" indication. Every novel mechanism (PI, IMiD, CD38 mAb, BCMA ADC, BCMA CAR-T, BCMA bispecific, GPRC5D bispecific) has followed the same arc: first-in-class receives AA on ORR in heavily pre-treated (≥4L) single-arm studies, then converts to traditional approval on randomised PFS in earlier lines within 2–4 years. MRD-negative CR is now the emerging registrational primary endpoint for 1L/2L combinations — sponsors designing pivotal MM studies today should default to MRD as co-primary or primary unless there is a specific reason not to.
EMA Regulatory Precedents — 53 matched records
| Drug (Brand) | MAH | Opinion Date | Pathway | Primary Endpoint | Benefit-Risk Theme |
|---|
| Teclistamab + Dara (Tecvayli) | Janssen | 21-Aug-26 | Standard MA | PFS | MajesTEC-3: PFS HR 0.17; OS HR 0.46 |
| Isatuximab SC (Sarclisa) | Sanofi | 04-Jun-26 | Traditional | ORR non-inf | IRAKLIA SC bridge to all IV indications |
| Belantamab mafodotin (Blenrep) | GSK | 23-Jul-25 | Traditional | PFS | DREAMM-7/-8 return after 2023 CMA non-renewal |
| Isatuximab-VRd (Sarclisa GMMG-HD7) | Sanofi | 18-Jul-25 | Standard MA | MRD negativity | 1L induction MRD as primary EU endpoint |
| Daratumumab (Darzalex AQUILA) | Janssen | 18-Jul-25 | Orphan | PFS | SMM: first pre-symptomatic MM approval |
| Linvoseltamab (Lynozyfic) | Regeneron | 23-Apr-25 | Conditional MA | ORR | LINKER-MM1: 70.9% ORR in ≥3L |
| Daratumumab-VRd (Darzalex MMY3019) | Janssen | 04-Apr-25 | Orphan | MRD negativity | 1L TI: MRD 53.3% vs 35.4% |
| Isatuximab-VRd (Sarclisa IMROZ) | Sanofi | 20-Jan-25 | Standard MA | PFS | 1L TI: PFS NR vs 54.3mo |
| Daratumumab-VRd (Darzalex PERSEUS/MMY3014) | Janssen | 21-Oct-24 | Orphan | PFS | 1L TE: MRD-guided discontinuation embedded in SmPC |
| Cilta-cel (Carvykti CARTITUDE-4) | Janssen | 19-Apr-24 | ATMP + Orphan | PFS | 2L line-expansion; CMA→standard MA conversion |
Showing 10 of 53 EMA precedents — prioritising PRIME-designated, Conditional MA, and most recent standard MA approvals. Visit the Analytics dashboards under the Analytics tab to explore all EMA precedents interactively. Nexus EMA Dataset
Landmark EMA Approval Profiles
Isatuximab-VRd (Sarclisa GMMG-HD7) — 18-Jul-25, Standard MA
Indication: Induction treatment of adult patients with newly diagnosed multiple myeloma eligible for ASCT (Part 1 of GMMG-HD7)
Endpoint: MRD negativity at 10⁻⁵ · Line: 1L · Class: CD38 mAb
The first EMA MM approval to use MRD negativity as the primary registrational endpoint. In GMMG-HD7 (N=662), the IVRd induction arm achieved 50.5% MRD-negativity versus 35.6% for VRd alone (OR 1.84, 95% CI 1.35–2.51; p<0.0001), supported by PFS HR 0.701 (95% CI 0.516–0.953; p=0.0113). This approval demonstrates that CHMP has aligned with FDA on MRD as a registrationally acceptable primary endpoint in 1L MM. Nexus EMA Dataset
Daratumumab SC (Darzalex AQUILA) — 18-Jul-25, Orphan / Standard MA
Indication: Monotherapy for adult patients with high-risk smouldering multiple myeloma
Endpoint: PFS (progression to MM) · Line: 1L SMM · Class: CD38 mAb
SMM3001/AQUILA (N=390) established the CHMP position that intervention in high-risk smouldering disease is justified by disease-modifying PFS benefit. Median PFS was not reached in the daratumumab arm versus 41.5 months in active monitoring, HR 0.49 (95% CI 0.36–0.67; p<0.0001). OS and PFS2 data were immature at the primary analysis. Grade 3–4 infections were higher in the daratumumab arm (16.1% vs 4.6%), primarily pneumonia — a key benefit-risk consideration given the treatment of an asymptomatic population. Nexus EMA Dataset
Blenrep (belantamab mafodotin) — 23-Jul-25, Standard MA (re-approval)
Indication: BVd combination for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy (DREAMM-7); BPd combination for patients previously treated with lenalidomide (DREAMM-8)
Endpoint: PFS ·
Line: 2L ·
Class: BCMA ADC
DREAMM-7 (BVd vs DVd, N=494) showed BVd nearly tripled median PFS versus daratumumab-based comparator (36.6 vs 13.4 months). This represents an extraordinary regulatory arc: CHMP granted CMA in Aug-20 on DREAMM-2 single-arm data, then in September 2023 CHMP recommended non-renewal of the conditional MA after confirmatory DREAMM-3 failed. Blenrep was withdrawn, then re-authorised on standard MA in Jul-25 based on the two positive DREAMM-7/-8 randomised trials (Dimopoulos et al., 2024
[17]). This is a rare case study in CMA non-renewal followed by full standard MA re-authorisation.
Nexus EMA Dataset
Ciltacabtagene autoleucel (Carvykti) — 19-Apr-24, ATMP + Orphan (line expansion)
Indication: Adult patients with relapsed and lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent
Endpoint: PFS · Line: 2L · Class: BCMA CAR-T
The 2L line-expansion approval was granted under standard MA legal basis via Type II variation to the original CMA (granted May-22 on CARTITUDE-1 ORR under CMA/PRIME/ATMP/Orphan). CARTITUDE-4 median PFS was not reached in the cilta-cel arm versus 11.8 months in SoC, HR 0.26 (95% CI 0.2–0.4). This illustrates the EU structural difference: the original CMA product-level status flows through to line-expansion variations regardless of the maturity of the confirmatory dataset. Nexus EMA Dataset
CHMP Intelligence: CHMP has embraced MRD as a registrational primary endpoint in 1L MM in 2024–2025, with three consecutive approvals (D-VRd MMY3014 PERSEUS Oct-24 with MRD-guided treatment discontinuation embedded in the SmPC; D-VRd MMY3019 CEPHEUS Apr-25; Isa-VRd GMMG-HD7 Jul-25) all using MRD as either primary or co-primary. The EU Blenrep non-renewal in Sep-23 remains the most consequential CMA-to-withdrawal case in oncology — sponsors relying on CMA for MM should plan confirmatory trial design assuming the DREAMM-3 outcome as a baseline risk, and note that Blenrep's return via DREAMM-7/-8 shows CHMP will re-engage constructively if the confirmatory evidence is compelling.
US/EU Regulatory Comparison & Divergence
US and EU MM approval sets are broadly aligned at the molecule level, with 20 of 22 FDA INNs also represented in the EMA dataset. The two significant US-only products in the current dataset are Xpovio/Nexpovio (selinexor — approved in both regions but with an important pathway divergence: FDA granted AA Jul-19 on STORM ORR over an 8–5 ODAC vote to delay, while EMA granted CMA in Mar-21 and only converted to standard MA in Jul-22 following BOSTON) and Pepaxto/Pepaxti (melflufen — FDA AA Feb-21 was voluntarily withdrawn in Oct-21 after OCEAN showed OS detriment, while EMA nonetheless granted standard MA Aug-22 restricted to a TCR subgroup, creating one of the sharpest FDA-EMA benefit-risk divergences in modern oncology).
The CMA-vs-AA pathway asymmetry is particularly instructive in MM. On the EMA side, Blenrep (CMA Aug-20 → non-renewed Sep-23 → standard MA Jul-25 on DREAMM-7/-8), Nexpovio (CMA Mar-21 → standard MA Jul-22), Elrexfio (CMA Dec-23), Talvey (CMA Aug-23), Lynozyfic (CMA Apr-25), Tecvayli (CMA Aug-22 monotherapy → standard MA Aug-26 for MajesTEC-3 combination), Abecma (CMA Aug-21 → standard MA line-expansion Mar-24), and Carvykti (CMA May-22 → standard MA line-expansion Apr-24 via Type II variation) all reflect CMA as the initial gateway for novel MOAs. Because CMA applies only at initial MAA, when Carvykti's CARTITUDE-4 line expansion was granted, it was legally a variation to the already-CMA product — the entire product moves to standard MA when the specific obligations are fulfilled. On the FDA side, each supplemental indication is its own AA/traditional decision — Carvykti's original 5L approval was actually traditional (Feb-22) and its 2L expansion was also traditional (Apr-24), while Abecma's original 5L (Mar-21) was traditional and its 3L (Apr-24) was also traditional. This structural difference means CMA product-count and AA indication-count are not comparable metrics.
Endpoint acceptance is now closely aligned. Both FDA and EMA have accepted MRD-negativity as primary in 1L MM combinations within the same 12-month window (FDA CEPHEUS Jan-26 and iberdomide Aug-26; EMA GMMG-HD7 Jul-25 and MMY3019 CEPHEUS Apr-25). For 5L+ single-arm BCMA/GPRC5D approvals, both agencies accept ORR with DoR as sufficient under AA/CMA. The most notable ongoing divergence is smouldering MM: FDA approved daratumumab in HR-SMM on 06-Nov-25 following a 6–2 ODAC vote; EMA approved on 18-Jul-25 under standard MA legal basis with orphan designation. Both agencies restricted the indication to the high-risk subset — a rare instance of harmonised pre-symptomatic disease intervention.
The single most consequential US/EU divergence in MM 2020–2025 is Pepaxto/Pepaxti (melflufen): withdrawn by FDA Oct-21 after OS detriment in OCEAN, but authorised by EMA Aug-22 in a TCR-restricted subgroup. This case demonstrates that CHMP will separately reweight benefit-risk in defined subgroups even when FDA has concluded the totality of evidence supports withdrawal — a strategic option worth exploring for sponsors with heterogeneous confirmatory trial signals.
Active Global Clinical Pipeline
The ClinicalTrials.gov registry returned 921 active/recruiting interventional trials for multiple myeloma. The top 50 Phase 3 industry trials listed in the retrieved data reveal an unprecedented concentration of pivotal-stage activity, dominated by BCMA/GPRC5D bispecifics, next-generation CAR-T, and CELMoD/degrader combinations.
Phase 3 competitive intensity is remarkable. In the BCMA CAR-T space alone, four industry-sponsored Phase 3 trials are recruiting head-to-head against standard of care: BMS-986393 (anitocabtagene autoleucel) versus SoC (NCT06615479, Juno/BMS), anitocabtagene autoleucel versus SoC (NCT06413498, Kite/Gilead), Eque-cel in lenalidomide-refractory RRMM (NCT06464991, IASO), and AstraZeneca's dual-targeted AZD0120 CAR-T (NCT07391657). AstraZeneca is running two additional AZD0120 Phase 3 studies: NDMM transplant-ineligible (NCT07764978) and post-induction consolidation (NCT07735637) — a rapid three-front assault on the entrenched BCMA CAR-T franchise.
The bispecific space is even more crowded. Janssen alone runs at least four Phase 3 studies: teclistamab-based combinations (NCT06208150, NCT05623020), ramantamig plus daratumumab in 1L (NCT07665450), and two head-to-head studies of JNJ-79635322 (a novel construct) versus teclistamab (NCT07518186, NCT07258511). Pfizer's elranatamab is in Phase 3 in combination with lenalidomide and daratumumab (NCT05623020) and MagnetisMM-32 (NCT06152575). Regeneron's linvoseltamab has multiple Phase 3 studies: versus daratumumab in HR-SMM (NCT07393282), monotherapy vs Kd combination (NCT07222761), and versus elotuzumab-Pd (NCT05730036). AbbVie's etentamig has two Phase 3 studies (NCT07728188, NCT06158841). GSK's Blenrep has three additional post-approval Phase 3 studies in Japanese and Chinese populations (NCT06956170, NCT06868667, NCT06868654) and the pivotal 1L combination trial (NCT06679101).
CELMoD/degrader class Phase 3 competition is emerging as the next major front. Iberdomide's post-approval consolidation is anchored by BMS-sponsored maintenance study versus lenalidomide (NCT05827016). CellCentric's inobrodib (CBP/p300 degrader) has entered Phase 3 versus SoC (NCT07772024) — the first non-cereblon degrader to reach Phase 3 in MM. Cevostamab (FcRH5-targeting bispecific from Roche) is in Phase 3 with pomalidomide-dexamethasone (NCT07555938) with MRD-negative CR as primary endpoint. A significant number of Chinese-sponsored Phase 3 studies (NCT07623798, NCT07569757, NCT07579234, NCT07452198, NCT07297329, NCT06508983, NCT07181239, NCT07138209) are testing regional BCMA-directed and CD38 biosimilar assets, reflecting China's parallel MM regulatory development track.
Primary endpoint composition across the top 50 Phase 3 trials is instructive: PFS remains the modal primary endpoint (present in ~35 trials), but MRD-negative CR or MRD-negativity appears as primary or co-primary in at least 10 trials (NCT07742215, NCT07735637, NCT07740486, NCT07555938, NCT07285239, NCT06413498, NCT06679101, NCT06932562, NCT06615479, NCT07297329) — a direct downstream consequence of the April 2024 ODAC endorsement. Geographic distribution is truly global, with US-anchored multinational designs for most Janssen, Regeneron, BMS, and Kite studies, EU-focused consolidation studies (Polish Myeloma Consortium NCT07740486; IFM NCT06918002; HOVON NCT06187441; EMN NCT06932562), and China-only regional development.
The single most strategically significant trial in the current landscape is JNJ-79635322 versus teclistamab (
NCT07518186) — Janssen running an active-controlled head-to-head against its own approved bispecific. This signals that Janssen believes the next-generation trispecific/optimised construct will supersede first-generation BCMA bispecifics, and it establishes a precedent for within-class active comparator trials that will likely become the new benchmark for BCMA-directed submissions.
Regulatory Pathway & Endpoint Strategy
The FDA pathway landscape in MM is defined by two decades of intensive Accelerated Approval usage followed by a maturity-driven pivot toward traditional approval on randomised PFS and MRD-negative CR. Of 54 FDA records, 14 (26%) used Accelerated Approval — concentrated overwhelmingly in the 5L+ single-arm setting for novel MOAs (Blenrep 2020, Talvey 2023, Elrexfio 2023, Tecvayli 2022, Lynozyfic 2025, iberdomide 2026). Every one of these AA approvals followed the same design: single-arm study of 100–200 patients with prior triple-class exposure, ORR (with DoR) as primary endpoint, and a mandatory confirmatory randomised trial. Twelve records carried Breakthrough Therapy designation, and 33 (61%) received Priority Review — one of the highest Priority Review densities of any indication in FDA history.
The Project Optimus impact on MM development has been substantial. Modern BCMA bispecific and CAR-T dossiers now include multiple randomised dose-optimisation cohorts embedded in Phase 1/2 designs. Talvey's approval explicitly includes two dose regimens (0.4 mg/kg QW and 0.8 mg/kg Q2W) with efficacy characterised for both, reflecting FDA's insistence on dose-response characterisation rather than MTD selection FDA Guidance: Cancer Clinical Trial Eligibility Criteria: Laboratory Values. Lynozyfic's LINKER-MM1 design included Phase 1 dose exploration prior to Phase 2 recommended dose confirmation. Project Frontrunner is directly visible in the BCMA class arc: teclistamab (5L Oct-22 AA → 2L MajesTEC-3 Mar-26 traditional), cilta-cel (5L Feb-22 traditional on 97.9% ORR → 2L CARTITUDE-4 Apr-24 traditional), and ide-cel (5L Mar-21 traditional → 3L KarMMa-3 Apr-24 traditional) all followed the Frontrunner logic of establishing efficacy in heavily pre-treated patients before pivoting to earlier lines with randomised evidence.
Confirmatory trial dynamics post the 2022 FDA Omnibus Act have been particularly consequential in MM. The two most instructive cases are Blenrep — where DREAMM-3 failure led to voluntary withdrawal in Nov-22, followed by DREAMM-7/-8 driving re-approval in Oct-25 — and Pepaxto, withdrawn Oct-21 after OCEAN showed OS detriment. Selinexor's BOSTON confirmed AA and enabled 2L expansion (Dec-20). These outcomes reinforce that FDA's confirmatory expectations are now unforgiving, and sponsors pursuing AA must ensure the confirmatory design is powered for meaningful PFS/OS benefit against a currently relevant SoC, not the SoC at the time of AA FDA Guidance: Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway.
The EMA pathway landscape shows a distinct pattern. Conditional Marketing Authorisation has been the primary vehicle for novel MOA introduction in MM: Darzalex CMA May-16, Ninlaro CMA Nov-16, Blenrep CMA Aug-20 (non-renewed Sep-23), Nexpovio CMA Mar-21 (converted Jul-22), Abecma CMA Aug-21 (converted Mar-24), Carvykti CMA May-22 (converted Apr-24), Tecvayli CMA Aug-22 (converted Aug-26), Talvey CMA Aug-23, Elrexfio CMA Dec-23, Lynozyfic CMA Apr-25. PRIME designation was granted for the T-cell redirectors (Carvykti, Abecma, Tecvayli, Talvey, Elrexfio, Blenrep) — reflecting CHMP's recognition of these as breakthrough tools. Notably, CMA is a product-level status: when Carvykti's 2L line expansion was granted via Type II variation to its CMA MAA (Apr-24), the variation was granted under standard MA legal basis. This is structurally different from FDA's indication-level AA, and sponsors must plan EU dossier strategy accordingly — a single CHMP benefit-risk determination flows across all indications of a CMA product upon conversion.
Endpoint acceptance is now closely convergent between agencies. Both FDA and EMA accept ORR + DoR for single-arm 5L+ AA/CMA. Both accept randomised PFS as the traditional-approval standard for 2L+ combinations. Both have now accepted MRD-negativity as primary in 1L combinations (FDA CEPHEUS/iberdomide 2026; EMA GMMG-HD7/CEPHEUS 2024–2025). The FDA draft guidance FDA Guidance: Minimal Residual Disease and CR in Multiple Myeloma_Supporting Accelerated Approval_Draft explicitly frames MRD-negativity as an acceptable AA endpoint but restricts its use in the maintenance setting, smouldering MM, MGUS, and extramedullary disease — sponsors developing in these subpopulations should default to PFS or OS. Circulating tumour DNA / molecular residual disease approaches remain outside the current MM regulatory frame but may enter as complementary endpoints given FDA's parallel guidance on ctDNA FDA Guidance: Use of Circulating Tumor DNA for Curative-Intent Solid Tumor Drug Development.
Project Orbis has been used aggressively in recent MM approvals — iberdomide (2026), teclistamab-dara (2026), talquetamab (2023), elranatamab (2023) all leveraged Orbis for parallel review with Australia, Canada, Switzerland, and Singapore. Sponsors filing in MM should default to Orbis participation given the demonstrated timeline compression and increasing familiarity of partner agencies with MM endpoints.
Pathway strategy for late entrants: The bar for traditional approval in MM has now decisively shifted. A late-entrant BCMA bispecific or CAR-T sponsor targeting 5L+ should recognise that FDA's expectation is no longer AA on ORR alone — the field is saturated with 60–80% ORR precedents, and FDA reviewers are increasingly requesting randomised confirmatory context at time of initial filing. Sponsors should consider skipping AA entirely and pursuing randomised evidence for traditional approval, or if pursuing AA, ensure the confirmatory trial is fully enrolling at time of BLA submission. For 1L combinations, MRD-negativity as primary/co-primary is now the field standard — a PFS-only 1L pivotal design in 2026 will underdeliver on reviewer expectations.
White Space & Strategic Opportunities
Despite the crowded landscape, the residual white space in MM is well-defined and clinically urgent. Each opportunity below is anchored in an unmet need documented in the peer-reviewed literature or an unmet regulatory gap visible in the dataset.
6Gaps Identified
3High Priority
4Unmet Need Gaps
2Mechanism Gaps
Post-BCMA / Post-GPRC5D Resistance
Patients progressing after both a BCMA and GPRC5D T-cell redirector represent the fastest-growing unmet-need population. Ma et al. (2025)
[5] documented genetic and epigenetic mechanisms of GPRC5D loss after CAR-T; Touzeau et al. (2024)
[14] quantified reduced teclistamab efficacy after prior BCMA exposure. Novel targets (FcRH5, CD138, SLAMF7 re-engagement) and trispecific constructs address this directly. High priority, high competitive intensity.
Extramedullary Disease (EMD)
EMD remains a poor-prognosis subset largely excluded from pivotal trial populations (0–11% enrolment across recent BCMA/GPRC5D pivotals). Spatial transcriptomics reveals profound T-cell dysfunction that likely explains resistance to T-cell redirectors (John et al., 2024
[11]; Bladé et al., 2022
[20]). No approved therapy is EMD-specific. Well-defined EMD-enriched trials with EMD as stratification factor represent a differentiated regulatory pathway with orphan potential.
Non-Cereblon Novel Degraders
The cereblon-modulating class (thalidomide, lenalidomide, pomalidomide, iberdomide, mezigdomide) has dominated MM protein degradation for 20 years. CellCentric's inobrodib (CBP/p300 degrader,
NCT07772024) is the first non-cereblon degrader to reach Phase 3, opening the door for parallel non-cereblon MOAs (BRD9, IKZF-independent degraders). Regulatory precedent for degrader mechanism is established via iberdomide's Aug-26 AA on MRD.
High-Risk Cytogenetics (del17p, t(4;14), 1q21+)
Present in 22–35% of trial populations but with heterogeneous subgroup benefit. The 2025 IMS/IMWG consensus (Avet-Loiseau et al., 2025
[7]) reframed high-risk MM around cumulative cytogenetic burden. No drug is specifically indicated or biomarker-selected for high-risk cytogenetics. FDA's MRD guidance explicitly welcomes biomarker-selected trials with appropriate justification.
MRD-Guided Fixed-Duration Therapy
PERSEUS/MMY3014 embedded MRD-guided treatment discontinuation in the EU SmPC — the first regulatory acceptance of MRD as a stopping rule. Substantial patient-relevant and cost-effectiveness opportunity exists in demonstrating that MRD-negative patients can safely discontinue maintenance. Regulatory frame is established; commercial models must adapt.
Frailty-Stratified 1L Regimens for Very Elderly
Transplant-ineligible patients >75 years remain under-served — most 1L quadruplet regimens (CEPHEUS, IMROZ, MAIA) enrolled a minority of ≥75-year-olds and dose intensity is a challenge. A dedicated frailty-adjusted regimen with regulatory-grade evidence would command differentiated access positioning across HTAs.
The single highest-value strategic opportunity is a bispecific or trispecific asset with pre-clinical evidence of activity in both BCMA-refractory and GPRC5D-refractory disease. This population is expanding rapidly as 2L BCMA approvals accelerate, and no approved therapy addresses it with reliable efficacy.
Strategic Implications for Development Teams
Default to MRD-negative CR as primary or co-primary in 1L combination pivotals. Following the April 2024 ODAC endorsement and both FDA and EMA accepting MRD in 2025–2026 approvals (CEPHEUS, IMROZ variants, GMMG-HD7, MMY3019, iberdomide), a 1L MM pivotal design in 2026 that uses PFS alone as primary will underdeliver on reviewer expectations and lose head-to-head competitive positioning. The MRD assay must meet analytical validation standards under GLP-equivalent QMS with inter-laboratory harmonisation — this is a critical Chemistry Manufacturing Controls / Central Lab planning item that must be addressed at IND, not at pivotal.
For BCMA/GPRC5D late entrants: skip AA and go direct to randomised traditional approval. The 5L+ AA precedent is saturated (Blenrep, Abecma, Carvykti, Tecvayli, Talvey, Elrexfio, Lynozyfic — all approved on ~30–70% ORR). A late-entrant sponsor pursuing AA on 60% ORR in triple-class-refractory patients now faces reviewer skepticism about incremental benefit and immediate competitive obsolescence given the 2L expansion trajectory. Randomised active-controlled Phase 3 (e.g., versus teclistamab, as JNJ-79635322 is doing in
NCT07518186) is now the differentiated regulatory position — and delivers a stronger reimbursement dossier for G-BA, NICE, and HAS.
EU dossier strategy: plan for CMA-to-standard MA conversion at time of first line-expansion. The EU regulatory frame flows differently from the US. If your first MAA is a CMA (as is nearly certain for a novel BCMA/GPRC5D asset), your first Type II variation for line expansion will be granted under standard MA legal basis but the specific obligations from the original CMA remain in force until CHMP conversion. The Blenrep 2023 CMA non-renewal precedent shows that CHMP will act decisively on confirmatory trial failure — sponsors should build the confirmatory trial dataset with the same rigour and timelines as the US confirmatory obligation, not treat it as a secondary submission.
Actively enroll extramedullary disease and high-risk cytogenetic patients with pre-specified subgroup analyses. These populations are systematically underrepresented in current pivotals and represent both a genuine unmet-need pathway and a strategic label-differentiation opportunity. FDA's biomarker-selected AA endpoint framework in the MRD draft guidance
FDA Guidance: Minimal Residual Disease and CR in Multiple Myeloma_Supporting Accelerated Approval_Draft explicitly welcomes biomarker-selected registrational designs when justified by natural history. Stratifying by extramedullary disease status and cytogenetic risk at randomisation — and pre-specifying formal subgroup analysis with hierarchical testing — creates the regulatory basis for a differentiated label claim in these subsets.
Use Project Orbis for every novel MM asset. Every recent BCMA/GPRC5D/degrader approval (Talvey, Elrexfio, Tecvayli 2026, iberdomide 2026) leveraged Project Orbis for parallel review with Australia, Canada, Switzerland, and Singapore. This delivers 3–6 months of ex-US launch timeline compression and, in HTA terms, allows synchronised value dossier submission across markets. Sponsors filing in MM without Orbis participation are leaving both regulatory and commercial value on the table.
References & Data Sources
Intelligence Sources
5010AI Nexus FDA Oncology Approvals Dataset · 2000–present · 25 records matched
5010AI Nexus EMA/EU Oncology Approvals Dataset · 20 records matched · CHMP opinions, conditional MAs, benefit-risk assessments
U.S. National Library of Medicine · 921 active trials retrieved · Live data as of Sep 6, 2026
NCBI PubMed E-utilities · 30 peer-reviewed articles · Live retrieval
FDA CDER/CBER guidance · EMA CHMP guidance & EPAR assessments · Kept current with rolling updates
Nexus = FDA proprietary dataset ·
EMA·[product] = EMA proprietary dataset ·
NCT····· = ClinicalTrials.gov ·
PMID····· = PubMed ·
FDA Guidance = regulatory document
For drug development strategy purposes only. Not for clinical decision-making. © 5010AI Nexus Intelligence Platform.
Nexus Intelligence Platform · nexus.5010ai.com · For drug development strategy purposes only.